“Dose-Modified Lenalidomide Induces Sustained Hematological Response in Patients With Intermediate to High Risk Myelodysplasia”. 2010. Mediterranean Journal of Hematology and Infectious Diseases 2 (2): e2010012. https://doi.org/10.4084/mjhid.2010.012.